Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.80
-0.04-2.44%
Pre-Market: 5:31 AM EDT
Comments
Loading...
Sana Biotechnology Analyst Ratings and Price Targets | NASDAQ:SANA | Benzinga
Sana Biotechnology Inc has a consensus price target of $9.5 based on the ratings of 8 analysts. The high is $15 issued by Citigroup on August 9, 2024. The low is $5 issued by Citizens Capital Markets on March 18, 2025. The 3 most-recent analyst ratings were released by Citizens Capital Markets, HC Wainwright & Co., and Jefferies on March 18, 2025, March 18, 2025, and March 14, 2025, respectively. With an average price target of $7.67 between Citizens Capital Markets, HC Wainwright & Co., and Jefferies, there's an implied 325.93% upside for Sana Biotechnology Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citizens Capital Markets
HC Wainwright & Co.
Jefferies
Citigroup
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Sana Biotechnology
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | Buy Now | 177.78% | Citizens Capital Markets | Reni Benjamin46% | → $5 | Upgrade | Market Perform → Market Outperform | Get Alert |
| 03/18/2025 | Buy Now | 511.11% | HC Wainwright & Co. | Emily Bodnar39% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2025 | Buy Now | 288.89% | Jefferies | Roger Song33% | → $7 | Initiates | → Buy | Get Alert |
| 01/08/2025 | Buy Now | 511.11% | HC Wainwright & Co. | Emily Bodnar39% | $8 → $11 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | — | TD Cowen | Marc Frahm23% | — | Upgrade | Hold → Buy | Get Alert |
| 11/27/2024 | Buy Now | 344.44% | HC Wainwright & Co. | Emily Bodnar39% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | 344.44% | HC Wainwright & Co. | Emily Bodnar39% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 11/05/2024 | Buy Now | — | JMP Securities | Reni Benjamin46% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 11/05/2024 | Buy Now | 344.44% | HC Wainwright & Co. | Emily Bodnar39% | $11 → $8 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | 733.33% | Citigroup | Samantha Semenkow33% | $8 → $15 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | 511.11% | HC Wainwright & Co. | Emily Bodnar39% | $12 → $11 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 566.67% | HC Wainwright & Co. | Emily Bodnar39% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 566.67% | HC Wainwright & Co. | Emily Bodnar39% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 733.33% | JMP Securities | Reni Benjamin46% | $8 → $15 | Maintains | Market Outperform | Get Alert |
| 01/16/2024 | Buy Now | 566.67% | HC Wainwright & Co. | Emily Bodnar39% | → $12 | Upgrade | Neutral → Buy | Get Alert |
| 10/12/2023 | Buy Now | 344.44% | JMP Securities | Reni Benjamin46% | $9 → $8 | Maintains | Market Outperform | Get Alert |
| 09/25/2023 | Buy Now | 400% | JMP Securities | Reni Benjamin46% | → $9 | Initiates | → Market Outperform | Get Alert |
| 09/05/2023 | Buy Now | 344.44% | Citigroup | Samantha Semenkow33% | → $8 | Initiates | → Buy | Get Alert |
| 08/14/2023 | Buy Now | — | TD Cowen | Marc Frahm23% | — | Initiates | → Market Perform | Get Alert |
| 05/02/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | — | Initiates | → Neutral | Get Alert |
| 01/24/2023 | Buy Now | 622.22% | Morgan Stanley | Matthew Harrison60% | $15 → $13 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 233.33% | Goldman Sachs | Salveen Richter53% | $7 → $6 | Maintains | Neutral | Get Alert |
| 05/17/2022 | Buy Now | 733.33% | Morgan Stanley | Matthew Harrison60% | $17 → $15 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Sana Biotechnology (SANA) stock?
The latest price target for Sana Biotechnology (NASDAQ:SANA) was reported by Citizens Capital Markets on March 18, 2025. The analyst firm set a price target for $5.00 expecting SANA to rise to within 12 months (a possible 177.78% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sana Biotechnology (SANA)?
The latest analyst rating for Sana Biotechnology (NASDAQ:SANA) was provided by Citizens Capital Markets, and Sana Biotechnology upgraded their market outperform rating.
When was the last upgrade for Sana Biotechnology (SANA)?
The last upgrade for Sana Biotechnology Inc happened on March 18, 2025 when Citizens Capital Markets raised their price target to $5. Citizens Capital Markets previously had a market perform for Sana Biotechnology Inc.
When was the last downgrade for Sana Biotechnology (SANA)?
The last downgrade for Sana Biotechnology Inc happened on November 5, 2024 when JMP Securities changed their price target from N/A to N/A for Sana Biotechnology Inc.
When is the next analyst rating going to be posted or updated for Sana Biotechnology (SANA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sana Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sana Biotechnology was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
Is the Analyst Rating Sana Biotechnology (SANA) correct?
While ratings are subjective and will change, the latest Sana Biotechnology (SANA) rating was a upgraded with a price target of $0.00 to $5.00. The current price Sana Biotechnology (SANA) is trading at is $1.80, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.